Lexeo Therapeutics, Inc. LXEO

LXEO Company Overview

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing adeno-associated virus (AAV)-based gene therapies for cardiovascular disease and APOE4-associated neurodegenerative conditions. The company operates within the biotechnology and genetic medicine industries, with a primary emphasis on rare and genetically defined diseases where there are limited approved therapeutic options. Lexeo’s core revenue and enterprise value are currently driven by research and development programs rather than commercialized products, as the company remains in the clinical development stage.

The company’s principal pipeline includes programs targeting inherited cardiomyopathies such as Friedreich ataxia cardiomyopathy and arrhythmogenic cardiomyopathy, as well as neurodegenerative indications linked to APOE4 genetics. Lexeo was founded in 2017 and emerged from research conducted at Weill Cornell Medicine. Its strategy has centered on leveraging translational academic research and precision gene delivery platforms to address diseases with identifiable genetic drivers. The company positions itself through a focused portfolio in cardiovascular gene therapy, a segment considered less crowded than broader oncology or metabolic gene therapy markets.